By Adriano Marchese
Recursion Pharmaceuticals plans to slash one-fifth of its workforce as it looks to streamline its operations.
The clinical-stage biopharmaceutical company said Tuesday it will reduce its workforce by about 20% as part of its efforts to streamline operating strategy and post-integration employee transitions.
Recursion said it expects to pay about $11 million in charges such as severance payments, employee benefits and other related costs this year.
Based on its revised expense profile and business plan after laying off its staff, Recursion said it now expects its projected cash runway to extend into the fourth quarter of 2027.
The Salt Lake City-based company also projects that its cash burn, excluding partnership inflows or one-time severance costs, to be less than $450 million in 2025 and less than $390 million in 2026, and noted that it could receive over $100 million in cash inflows from progress-based milestone payments from partners by the end of 2026.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
June 10, 2025 06:47 ET (10:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。